SEC Form 3 filed by new insider Poetting Sierk
$BNTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares | 449,387 | I | See Footnote(1) |
| Ordinary Shares | 141,514 | D | |
| Ordinary Shares | 1,638 | I | See Footnote(2) |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Option (right to buy) | 05/22/2027(3) | 05/22/2033 | Ordinary Shares(4) | 18,416 | $113.94(5) | D | |
| Option (right to buy) | 08/26/2028(3) | 08/26/2034 | Ordinary Shares(4) | 25,459 | (5)(6) | D | |
| Option (right to buy) | 05/28/2029(3) | 05/28/2035 | Ordinary Shares(4) | 8,838 | (5)(7) | D | |
| Phantom Option | 05/12/2025(3) | 05/12/2031 | Ordinary Shares(8) | 7,112 | $185.23(5) | D | |
| Phantom Option | 05/31/2026(3) | 05/31/2032 | Ordinary Shares(8) | 14,664 | $152.1(5) | D | |
| Performance Share Unit | 05/27/2029(9) | 05/27/2035 | Ordinary Shares(9) | 11,047 | $0 | D | |
| Explanation of Responses: |
| 1. The ordinary shares are held by Tofino GmbH. The Reporting Person is the sole shareholder of Tofino GmbH and may be deemed to beneficially own the ordinary shares held by Tofino GmbH. |
| 2. The ordinary shares are held by the Reporting Person's immediate family. The Reporting Person disclaims beneficial ownership of the ordinary shares noted herein except to the extent of his pecuniary interest therein. |
| 3. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. |
| 4. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board. |
| 5. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price. |
| 6. The exercise price of this option is EUR 75.91. |
| 7. The exercise price of this option is EUR 93.35. |
| 8. Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price. |
| 9. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date. |
| Remarks: |
| Exhibit List - Exhibit 24 - Power of Attorney |
| /s/ Humza Bokhari, Attorney-in-Fact | 03/18/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||